KRAS is one of the most frequently mutated oncogenes in NSCLC and 90% of these mutations affect codon 12, in which the glycine (G) can be replaced with aspartic acid (D), valine (V), or cysteine (C), the G12C substitution being the most frequent. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.